Reopening the Economy

Episode Summary

Executive Summary: The episode examines how the U.S. can safely reopen after COVID-19 shutdowns, emphasizing phased reopening, strong testing/contact tracing, and targeted protections for vulnerable groups. Experts Zeke Emanuel, Mark McClellan, and Barry Bloom argue that reopening must be gradual, region-specific, and reversible, while economic recovery may lag if consumers remain fearful. Vaccines and treatments are promising but still months away.

Main Topics: Phased reopening strategy (Priority: 5/5): Both experts support a stepwise reopening, starting with lower-risk businesses and activities that allow distancing, then moving cautiously to higher-risk gatherings. Shortcomings of federal reopening guidelines (Priority: 5/5): Emanuel praises the phase concept and vulnerable-population protections but criticizes the trigger metrics, lumping together very different gathering types, and lack of a resurgence plan. Testing and contact tracing as core infrastructure (Priority: 5/5): The discussion stresses that reopening safely requires far more testing, including regular testing of frontline workers and improved detection of asymptomatic spreaders. Local, reversible restrictions if cases rise (Priority: 4/5): Experts warn policymakers should not wait for exponential growth; even small upticks should trigger quick, incremental pauses or rollbacks, potentially by region. Demand-side limits to economic recovery (Priority: 4/5): Emanuel argues reopening does not automatically restore activity because consumer fear and low mobility may persist until testing and reassurance improve. Immunity, herd immunity, and antibody testing (Priority: 4/5): Bloom and McClellan caution that current evidence is insufficient to rely on herd immunity, since most Americans are still likely susceptible and antibody tests remain imperfect. Vaccines and treatments on accelerated timelines (Priority: 5/5): The guests see vaccines as likely 12-18+ months away but still record-fast, while some treatments may arrive sooner, potentially by late summer or fall.

Key Arguments: Reopening should happen in phases, with low-risk sectors and activities first, and higher-density events much later. Hospital capacity matters, but reopening should be tied more to low absolute infection levels than to a fixed number of declining days. Restaurants, offices, schools, and camps can reopen earlier than large social events or sports because distancing is more feasible. Safe reopening requires robust surveillance: widespread testing, repeat testing of frontline workers, and aggressive contact tracing. Asymptomatic 'super spreaders' must be found through random sampling and technology, not only symptom-based testing. If cases rise, policymakers must act quickly with incremental restrictions before exponential growth takes hold. Economic recovery may remain weak even after reopening because many consumers will continue to avoid risk. Herd immunity is not a near-term solution because most Americans likely remain unexposed and not immune. Vaccines are moving faster than any previous vaccine development effort, but manufacturing and distribution capacity are major bottlenecks. Some treatments may become available sooner than vaccines and could help reduce mortality and severe disease.

Data Points: Testing volume (U.S.): about 130,000 a day - Emanuel says current testing is far below what is needed for safe reopening. Suggested testing minimum: 500,000 a day - Emanuel cites this as the minimum level he has seen for adequate reopening surveillance. Preferred testing scale: 2 million a day - Emanuel argues broad surveillance and frontline-worker testing could require this level. Frontline workers to test weekly: 7 million people - Emanuel estimates this group alone would require about one million tests per day if tested weekly. Opening trigger infection level: around 20 per million population - Emanuel says reopening should depend on low absolute infection rates, not just 14 days of decline. Potential immunity exposure in communities: 5% to 10% - McClellan says antibody studies suggest exposure may be several times higher than positive case counts, but still a small share. Vaccine timeline: 12 to 18 months, possibly longer - Bloom says vaccine development remains the ultimate solution but will take substantial time. Clinical trials underway or planned: 440 - Bloom highlights the unusually large number of COVID-19 treatment trials. Protection from reinfection: unclear; possibly at least 2 years - Bloom says evidence is not yet clear, but he would expect meaningful antibody protection to last around two years. Low child mortality threshold: below 19 years old; even below 30 is rare - Emanuel uses this to support schools/camps as lower-risk places to trial reopening.

Pivotal Quotes: "I think the notion of just dialing up the dimmer gradually with pause for a few weeks at each step is important." — Dr. Mark McClellan: On why reopening must be slow, staged, and monitored before each next step. "You don't want to wait for exponential growth to reimpose some of the restrictions because the number you see today reflects what happened 14 or more days ago." — Dr. Zeke Emanuel: On the need to react early to rising cases due to reporting lag. "Vaccines are going to take a year and a half, and I would guess it wouldn't surprise me even longer." — Dr. Barry Bloom: On the timeline for a durable pharmaceutical solution to COVID-19.

Implications: Policy should prioritize phased, reversible reopening backed by testing, tracing, and local containment. Economies may recover unevenly because fear suppresses demand; vaccines and better treatments are crucial but not immediate.